undamentalytics Newsletter
Sign in

Entrada Therapeutics, Inc. revenue

Entrada Therapeutics, Inc.'s revenue was $25.4m in fiscal 2025, down 87.9% on the year before. Over the last twelve months it was $4.7m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue129211255
Growth on the year before—+63.4%−87.9%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Entrada Therapeutics, Inc. $4.7m -94.1% —
Bolt Biotherapeutics, Inc. $4.7m 12.8% -11.5%
Ocugen, Inc. $4.6m -3.7% 26.3%
Rani Therapeutics Holdings, Inc. $4.9m 306.4% —
Ensysce Biosciences, Inc. $4.5m -39.3% 14.6%
Adlai Nortye Group Ltd. $5.0m — —

Compare with peers

Head to head: BOLT vs TRDAOCGN vs TRDARANI vs TRDAENSC vs TRDA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Entrada Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Entrada Therapeutics, Inc.